Inari Medical (Inari Medical) Cash Flow from Financing : $1.2 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Inari Medical Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, Inari Medical received $0.0 Mil more from issuing new shares than it paid to buy back shares. It received $0.0 Mil from issuing more debt. It paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.0 Mil from paying cash dividends to shareholders. It spent $2.4 Mil on other financial activities. In all, Inari Medical spent $2.4 Mil on financial activities for the three months ended in Dec. 2023.

Inari Medical Cash Flow from Financing Historical Data

The historical data trend for Inari Medical's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inari Medical Cash Flow from Financing Chart

Inari Medical Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow from Financing

Get a 7-Day Free Trial

10.22

144.12

4.07

177.14

1.17

Inari Medical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash Flow from Financing	Get a 7-Day Free Trial															-1.69	2.47	-2.35	3.47	-2.41

Inari Medical Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Inari Medical's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

	Cash Flow from Financing		(A: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	9.921	+	0	+	0	+	0	+	0	+	-8.75
=	1.2

Inari Medical's Cash from Financing for the quarter that ended in Dec. 2023 is:

	Cash Flow from Financing		(Q: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0.001	+	0	+	0	+	0	+	0	+	-2.411
=	-2.4

Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.2 Mil.

Inari Medical (NAS:NARI) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Inari Medical's issuance of stock for the three months ended in Dec. 2023 was $0.0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Inari Medical's repurchase of stock for the three months ended in Dec. 2023 was $0.0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Inari Medical's net issuance of debt for the three months ended in Dec. 2023 was $0.0 Mil. Inari Medical received $0.0 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Inari Medical's net issuance of preferred for the three months ended in Dec. 2023 was $0.0 Mil. Inari Medical paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Inari Medical's cash flow for dividends for the three months ended in Dec. 2023 was $0.0 Mil. Inari Medical received $0.0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Inari Medical's other financing for the three months ended in Dec. 2023 was $-2.4 Mil. Inari Medical spent $2.4 Mil on other financial activities.

Inari Medical Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Inari Medical's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Inari Medical (Inari Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Inari Medical Inc (NAS:NARI) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

IM7:Germany

Address

6001 Oak Canyon, Suite 100, Irvine, CA, USA, 92618

Website

https://www.inarimedical.com

Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism. The company generates revenue from the sale of ClotTriever and FlowTriever systems directly to hospitals located in the United States. Majority of revenue is generated from FlowTriever system.

Executives

William Hoffman	director, officer: President and CEO	C/O INARI MEDICAL, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Mitch C. Hill,	officer: Chief Financial Officer	1009 TENNYSON DRIVE, SOUTHLAKE TX 76902
Andrew Hykes	officer: Chief Operating Officer	C/O INARI MEDICAL, INC., 9 PARKER AVENUE, SUITE 100, IRVINE CA 92618
Thomas Tu	officer: Chief Medical Officer	C/O INARI MEDICAL, INC., 9 PARKER AVENUE, SUITE 100, IRVINE CA 92618
Donald B Milder	director	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Robert Keith Warner	director	C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Catherine M. Szyman	director	C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Cynthia L Lucchese	director	7966 N. ILLINOIS STREET, INDIANAPOLIS IN 46260
Mead Dana G Jr.	director	2750 SAND HILL ROAD, MENLO PARK CA 94025
Rebecca Chambers	director	3052 ORCHARD DR., SAN JOSE CA 95134
Jonathan D Root	director	2735 SAND HILL ROAD, MENLO PARK CA 94025
Cooperatieve Gilde Healthcare Iv U.a.	10 percent owner	NEWTONLANN 51, UTRECHT P7 3508AB
Kirk G. Nielsen	director, 10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Gilde Healthcare Iv Management B.v.	10 percent owner	NEWTONLAAN 91, UTRECHT P7 3584 BP
Gilde Healthcare Holding B.v.	10 percent owner	NEWTONLAAN 91, PO BOX 85067, 3508 UTRECHT P7 AB